Hill April 17, 2023
By JC Scott

The drug pricing debate in Washington has kicked back into high gear, and it is more contentious, convoluted and misguided than ever. Who’s on what team? Whose “turn” is next? And, most importantly, what is in the best interest of patients and taxpayers? These questions may sound rhetorical, but they’re questions that Congress should be asking. 

Here’s why: Navigating complex and divergent drug pricing proposals can be challenging, yet the formula for determining what should get a “yes” or “no” vote should be quite simple. First: Support bills that will lower drug prices and make prescription drugs and health benefits more affordable for patients. Second: Oppose bills that would limit options and raise costs for patients, employers and taxpayers....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Regulations
What is a Consumer Health Company? Riffing Off of Deloitte’s Report on CHCs/A 2Q2025 Look at Self-Care Futures
The Key to Solving Medication Errors is At The Intersection of Technology and Standards
Medicaid cuts could hurt older adults who rely on home care, nursing homes
Avoidable deaths dropped worldwide – but not in the US
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services

Share This Article